Retatrutide for weight loss: A clinical overview
Retatrutide is redefining obesity treatment with its triple-action mechanism targeting GLP-1, GIP, and glucagon receptors. Offering 24.2% weight loss in 48 weeks, it outperforms Semaglutide and Tirzepatide, making it a potential game-changer for complex obesity cases.
